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LETTERS TO THE EDITORRegarding “SVS practice guidelines for the care of
patients with an abdominal aortic aneurysm:
Executive summary”
In the executive summary of the new Society for Vascular Surgery
(SVS) practice guidelines for abdominal aortic aneurysm (AAA),
Chaikof et al1 state, in reference to the United Kingdom Small
Aneurysm Trial (UKSAT) and Aneurysm Detection and Manage-
ment (ADAM) trials, that “a trend towards a beneficial effect of early
surgery was observed in both studies in the younger patient and for
those with larger aneurysms.” This is incorrect; in Table 2 of the
ADAM trial report,2 the relative risks for the youngest patients (age
50-59) and for the largest AAA (5.0-5.4 cm) are each given as 1.02,
representing a slight trend favoring surveillance. The authors then
state that “Young healthy patients, and especially women, with AAA
between 5.0 and 5.4 cm may benefit from early repair.” ADAM
patients were selected for good health, so the “young healthy pa-
tients” statement, too, is refuted by the published relative risk given
above. As for “especially women”, the same UKSAT report that noted
a higher rupture rate in women also reported a hazard ratio in women
of 0.99, indicating no benefit from repair of AAA smaller than 5.5
cm.3 Similar statements to the two quoted above appear in the
accompanying full report of the practice guidelines.4 Both articles
present in detail their recipe for preparing an evidence-based report,
but as always, the proof is in the pudding.
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Reply
We thank Dr Lederle for his comments. The United Kingdom
Small Aneurysm Trial (UKSAT) and Aneurysm Detection and
Management (ADAM) trials were large well-conducted investiga-
tions. Both studies demonstrated that there was no long-term
survival advantage with immediate open surgery compared to
selective surveillance among individuals with asymptomatic ab-
dominal aortic aneurysms (AAA) between 4.0 and 5.5 cm in
diameter. Dr Lederle is correct in noting the absence of benefit or
trend toward benefit among those participants in the ADAM trial
with aneurysms between 5 and 5.4 cm or younger patients be-
tween 50 and 59 years of age.As noted in the Society for Vascular Surgery Practice Guide-
lines documents,1,2 neither the UKSAT, the ADAM study, nor
the more recent CEASAR or PIVOTAL trials that compare
immediate endovascular aneurysm repair (EVAR) with surveil-
lance and selective EVAR were designed or powered for analysis
of patient subgroups that continue to be of interest to those
practitioners who care for patients with AAA. Specifically, dif-
ferential outcomes associated with older or younger cohorts,
aneurysm size, female patients, or those of exceptional physio-
logic fitness could not be addressed by these studies with
certainty. As the investigators in the ADAM trial have noted,
their cohort consisted of essentially men with fewer than 10
women enrolled in the study.3 Likewise, less than 10% of
patients in this trial were between 50 and 59 years of age
(98/1136; 8.6%) and likely only a proportion of these patients
presented with larger aneurysms (5-5.4 cm). In the UKSAT, the
estimated adjusted hazard ratios were in the direction of greater
benefit of early surgery for younger patients and those with larger
aneurysms but statistical significance was not demonstrated.4 Al-
though more women were enrolled in the UKSAT, over 80% of
trial participants were men.
With these and other studies in mind, the Practice Guidelines
documents state the following recommendation:
Young, healthy patients, and especially women, with AAA be-
tween 5.0 and 5.4 cm in maximum diameter may benefit from
repair.
Level of recommendation: Weak
Quality of evidence: Low
and noted the following areas in need of further research:
● Management recommendations for EVAR vs surveillance and
selective treatment for AAA 5.5 cm.
● Examination of the survival effect of immediate treatment vs
surveillance and selective treatment for specific AAA size (4.0
to 4.4 cm, 4.5 to 4.9 cm, and 5.0 to 5.5 cm), age, gender, and
fitness subgroups.
● Scales of fitness for surgical or endovascular intervention.
● Management recommendations for AAA in women and
minorities.
Given the limitations of subgroup analyses and related data,
and the evolution of endovascular technology for AAA repair, a
weak recommendation was recorded reflecting that the benefits
and risks for this recommendation are closely balanced. Further,
the quality of evidence for this recommendation was scored as low
since we believe further research is necessary and will very likely
change the estimate of the effect.
It was the consensus of the committee that there remains
therapeutic uncertainty for AAA in the range of 4.0 to 5.4 cm.
Ultimately, all recommendations are individualized.
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